Ignite Creation Date:
2024-05-06 @ 9:00 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02876081
Status:
WITHDRAWN
Last Update Posted:
2017-09-11
First Post:
2016-08-18
Brief Title:
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma Harboring Wild-type EGFR Expressing the Neurotensin - Neurotensin Receptor Complex
Sponsor:
Fondation Hôpital Saint-Joseph
Organization:
Fondation Hôpital Saint-Joseph
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2017-09-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-12
Completion Date Type:
ESTIMATED
First Submit Date:
2016-08-18
First Submit QC Date:
August 22 2016
Study First Post Date:
2016-08-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-09-07
Last Update Post Date:
2017-09-11
Last Update Post Date Type:
ACTUAL